Skip to main content
. 2024 Sep 5;16(9):e68748. doi: 10.7759/cureus.68748

Figure 1. Diagrammatic presentation of the molecular mechanisms of IL-2 therapy in promoting immune tolerance in SLE.

Figure 1

SLE: Systemic Lupus Erythematosus, IL-2: Interleukin-2, CD4+: Cluster of Differentiation 4 Positive, IL-2R: Interleukin-2 Receptor, IL-2Rα: Interleukin-2 Receptor Alpha, CD25: Cluster of Differentiation 25, IL-2Rβ: Interleukin-2 Receptor Beta, CD122: Cluster of Differentiation 122, IL-2Rγ: Interleukin-2 Receptor Gamma, CD132: Cluster of Differentiation 132, JAK-STAT: Janus Kinase-Signal Transducer and Activator of Transcription, PI3K-Akt: Phosphoinositide 3-Kinase-Akt, MAPK: Mitogen-Activated Protein Kinase, Tregs: Regulatory T Cells, STAT5: Signal Transducer and Activator of Transcription 5, Foxp3: Forkhead Box Protein P3, CTLA-4: Cytotoxic T-Lymphocyte-Associated Protein 4, IL-10: Interleukin-10, Teffs: Effector T Cells, IFN-γ: Interferon Gamma, IL-17: Interleukin-17, TNF-α: Tumor Necrosis Factor Alpha, NK: Natural Killer

Image credits: Gurjot Singh